Newsroom

Sorted by: Latest
-

Rosen Law Firm Encourages Nutanix, Inc. Investors to Inquire About Securities Class Action Investigation – NTNX

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Nutanix, Inc. (NASDAQ: NTNX) resulting from allegations that Nutanix may have issued materially misleading business information to the investing public. So What: If you purchased Nutanix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement....
-

GlobalAir.com Partners With AERO Friedrichshafen to Develop Pre-Owned Aircraft Area

LOUISVILLE, Ky.--(BUSINESS WIRE)--GlobalAir.com has been named the official sales representative for the pre-owned aircraft market at AERO Friedrichshafen....
-

A Concept Medical anuncia a inclusão do primeiro paciente no estudo clínico randomizado STARS DAPT, que avalia o stent farmacológico sem polímero Abluminus NP

TAMPA, Flórida--(BUSINESS WIRE)--A Concept Medical Inc., pioneira global em tecnologia inovadora de administração de medicamentos, tem o orgulho de anunciar a inclusão bem-sucedida do primeiro paciente no estudo clínico randomizado e controlado STARS DAPT (ST-Infarto do miocárdio com elevação do segmento ST tratado com um stent farmacológico sem polímero, com liberação de sirolimus por nanocarreador, e uma estratégia de terapia antiplaquetária única baseada em inibidor de P2Y12 após um curto pe...
-

Concept Medical inscribe los primeros pacientes en el ensayo clínico aleatorizado STARS DAPT, que evalúa el stent liberador de medicamentos sin polímeros Abluminus np

TAMPA, Florida--(BUSINESS WIRE)--Concept Medical Inc., pionera mundial en tecnología innovadora para la administración de medicamentos, se enorgullece de anunciar la incorporación satisfactoria de los primeros pacientes al estudio STARS DAPT ( ST -Segment Elevation Myocardial Inf A rction treated with a Polymer-Free Sirolimus-based Nanocarrie R Eluting Stent and a P2Y12 inhibitor-based S ingle Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional D ual A nti P latele...
-

Samenvatting: Concept Medical kondigt de registratie aan van de eerste patiënten in de STARS DAPT gerandomiseerde klinische studie waarin Abluminus NP polymeervrije DES wordt beoordeeld

TAMPA, Fla.--(BUSINESS WIRE)--Concept Medical Inc., een wereldwijde pionier in innovatieve technologie voor toediening van geneesmiddelen, kondigt trots de succesvolle registratie aan van de eerste patiënten in de STARS DAPT ( ST -Segment Elevation Myocardial Inf A rction (= myocardinfarct met ST-segmentstijging) behandeld met een polymeervrije, op sirolimus gebaseerde nanocarrie R eluting stent en een op P2Y12 remmer gebaseerde S ingle Antiplatelet Strategie na een korte Dual Antiplatelet Ther...
-

Concept Medical kündigt die erste Patientenaufnahme in die randomisierte klinische Studie STARS DAPT zur Bewertung des Abluminus NP polymerefreien DES an

TAMPA, Florida--(BUSINESS WIRE)--Concept Medical Inc., ein globaler Pionier auf dem Gebiet innovativer Wirkstofffreisetzungstechnologien, freut sich, die erfolgreiche Aufnahme der ersten Patienten in die randomisierte kontrollierte STARS DAPT ( ST -Segment Elevation Myocardial Inf A rction treated with a Polymer-Free Sirolimus-based Nanocarrie R Eluting Stent and a P2Y12 inhibitor-based S ingle Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional D ual A nti P latel...
-

Concept Medical annonce le recrutement du premier patient dans l'essai clinique randomisé STARS DAPT qui évalue l'Abluminus np, un DES sans polymère

TAMPA, Floride--(BUSINESS WIRE)--Concept Medical Inc., un pionnier mondial dans la technologie innovante d'administration de médicaments, est fier d'annoncer l'inscription des premiers patients dans l'essai contrôlé randomisé STARS DAPT ( ST -Segment Elevation Myocardial Inf A rction treated with a Polymer-Free Sirolimus-based Nanocarrie R Eluting Stent and a P2Y12 inhibitor-based S ingle Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional D ual A nti P latelet T h...
-

Riassunto: Concept Medical annuncia l'arruolamento del primo paziente in STARS DAPT, il trial clinico randomizzato di valutazione del DES senza polimeri Abluminus NP

TAMPA, Fla.--(BUSINESS WIRE)--Concept Medical Inc., un pioniere globale nella tecnologia innovativa del rilascio di farmaci, è lieta di annunciare il reclutamento dei primi pazienti nello studio clinico randomizzato controllato STARS DAPT ( ST -Segment Elevation Myocardial Inf A rction treated with a Polymer-Free Sirolimus-based Nanocarrie R Eluting Stent and a P2Y12 inhibitor-based S ingle Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional D ual A nti P latelet T...
-

コンセプト・メディカル、Abluminus NPポリマーフリーDESを評価するSTARS DAPT無作為化臨床試験で初の患者登録を達成

フロリダ州タンパ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 革新的なドラッグデリバリー技術を手がける世界的なパイオニアであるコンセプト・メディカル（Concept Medical Inc.）は、無作為化比較試験「STARS DAPT（ ST -Segment Elevation Myocardial Inf A rction treated with a Polymer-Free Sirolimus-based Nanocarrie R Eluting Stent and a P2Y12 inhibitor-based S ingle Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional D ual A nti P latelet T herapy）（ポリマーフリーのシロリムス系ナノキャリア溶出ステントで治療したST上昇型心筋梗塞（STEMI）患者を対象に、短期の抗血小板薬2剤併用療法後にP2Y12阻害薬を用いた単剤抗血小板療法と従来の抗血小板薬2剤併用療...
-

Port of Los Angeles Selects Pacific Cruise Terminals, LLC as Developer and Operator of Two Cruise Centers

LOS ANGELES--(BUSINESS WIRE)--Port of Los Angeles Selects Pacific Cruise Terminals, LLC as Developer and Operator of Two Cruise Centers...